Cognitive improvements and reduction in amyloid plaque deposition by saikosaponin D treatment in a murine model of Alzheimer's disease

LI ZHOU, JIN-YUAN HUANG, DI ZHANG and YA-LIANG ZHAO

Health Management Center, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, Hubei 430014, P.R. China

Received August 15, 2019; Accepted April 17, 2020

DOI: 10.3892/etm.2020.8760

Abstract. Alzheimer's disease (AD), is a severe neurodegenerative disease that currently lacks an optimally effective therapeutic agent for its management. Saikosaponin D (SSD) is a component extracted from the herb *Bupleurum falcatum* that is commonly used in Chinese medicine. Although SSD has been reported to exert neuroprotective effects, its pharmacological role in AD has not been previously elucidated. Therefore, the aim of the present study was to investigate whether SSD treatment improves the cognitive function and pathological features of 3xTg mice, a triple-transgenic mouse model of AD that displays classical pathological features of AD. The effects of SSD treatment on the behavioral, histological and physiological features of the animal were quantified. Results from the behavioral experiments on the SSD-treated 3xTg mice identified a significant reduction in memory impairment. In addition, histological staining results indicated that SSD application could preserve the morphology of neurons, reduce apoptosis and significantly inhibit amyloid-β deposition in the hippocampus of 3xTg mice. SSD treatment also decelerated the activation of microglia and astrocytes in the hippocampus of 3xTg mice, possibly via the inhibition of the NF-κB signal transduction pathway. Therefore, the present study demonstrated the protective effects of SSD against progressive neurodegeneration and identified the potential underlying pharmacological mechanism. It was speculated that SSD may serve as a possible therapeutic agent in AD treatment in the future.

Introduction

Alzheimer's disease (AD) is a neurodegenerative disorder with major clinical manifestations of dementia, memory impairment and language deficits (1). The incidence of AD is increasing with an ageing population worldwide, where it has become the 4th major life-threatening disease in the elderly, after heart disease, cancer and stroke (2). By 2040, the total number of patients with AD is expected to reach 80 million worldwide (2). However, effective treatment modalities for the management of this disease are currently limited.

The pathological mechanisms of AD are complex and are not fully understood. Previous studies have reported that the primary pathology of AD involves the excessive deposition of amyloid plaques, particularly those of amyloid β-peptide (Aβ), throughout the frontal and temporal cortices and the hippocampus (3). Additionally, neurofibrillary tangles and selective neuronal loss due to the accumulation of Aβ contribute to the onset of dementia in patients with AD (4). It has also been revealed that Aβ generation is associated with the activation of glia cells (5) and contributes to the release of inflammatory cytokines.

Saikosaponin is a triterpenoid glycoside extracted from *Bupleurum falcatum*, a herb that is used in traditional Chinese medicine (6). Based on its chemical structure, saikosaponin is classified into saikosaponin A (SSA), saikosaponin B (SSB), saikosaponin C (SSC) and saikosaponin D (SSD), of which SSD exhibits the strongest pharmacological activity (7). Previous studies have reported that SSD has sedative, anti-inflammatory, anti-fibrotic and immune-regulatory properties (8,9). In terms of neurological disorders, SSD has been found to promote apoptosis and inhibit the growth of glioblastomas (10). In addition, SSD exhibit potential anti-depressant properties via its ability to regulate inflammatory factors, enhance neurotrophic factor expression, increase neurotransmitter levels and downregulate the activity of the hypothalamic-pituitary-adrenal axis (11).

A previous study has demonstrated that SSC can suppress the release of Aβ and tau in human SH-SY5Y and H4 cells (12). Therefore, it was hypothesized that SSD can reduce Aβ deposition in the mouse brain, in turn alleviating memory impairment that is associated with AD. In the present study, the effect of SSD on the aforementioned factors were examined in a 3xTg mouse model. In addition, the therapeutic efficacy of SSD against cognitive deficits was evaluated in this mouse model, where the mechanism underlying its neuroprotective effects were investigated.
Materials and methods

**Animals and SSD treatment.** In total, 30 3xTg mice (age, 9 months; weight, 30-35 g, 16 male and 14 female), which simulated the pathological features of AD and 15 wild-type (WT, age, 9 months; weight, 30-35 g, 8 male and 7 female) control mice were obtained from the Shanghai Research Center for Model Organisms (Shanghai, China). Animals were housed at room temperature (23±1˚C), 60-65% humidity-controlled, with 12 h light/dark cycles in specific-pathogen-free conditions and were allowed free access to food and water. All experiments were performed according to the Guidelines for Animal Experimentation issued by the Ministry of Science and Technology of China. All animal experiments were approved by the Ethics Committee for Animal Experimentation of the Wuhan Hospital of Traditional Chinese Medicine (approval no. SYXK-2018-0213; Wuhan, China).

Mice were randomly divided into three groups: i) Control (WT, n=15); ii) 3xTg mice with no treatment (3xTg, n=15); and iii) 3xTg mice with SSD treatment (3xTg + SSD, n=15). Based on the previously published pharmacodynamic and pharmacokinetic information regarding SSD (13), SSD (Nacalai Tesque, In.) was administered by gavage (10 mg/kg dissolved in 0.3% DMSO) twice a day for 28 days in the 3xTg + SSD group, whilst the WT and 3xTg groups were gavaged with vehicle (0.3% DMSO). Following the behavioral tests, the mice were euthanized by decapitation to collect brain tissues.

**Morris water maze (MWM) protocol.** The MWM test is a widely applied method for testing memory and was conducted in a circular plastic pool with a height of 35 cm and a diameter of 100 cm filled with water and the temperature maintained at 23±1˚C. The surface of the water was set 1 cm above the platform, where the mice were placed in a random quadrant each time. The mice were trained to find the platform the day before the experiment, following which the time spent to find the platform was recorded consecutively for a period of 5 days, with the test performed three times per day. Each trial was ended after 60 sec or after the mice reached the platform and remained on it for 2 sec. On day 6, the platform was dismantled. The time taken by the mice to enter the quadrant in which the platform was located for the first time was recorded. All the data were analyzed using the SMART-CS 3.0 (Panlab) program. A quiet environment was maintained throughout the duration of the experiment.

**Y-maze protocol.** At the end of the 28 day treatment, an elevated Y-maze test was used to evaluate spatial cognitive ability. The elevated Y-maze used was comprised of a three-arm horizontal maze (length, 40 cm; width, 3 cm; height, 12 cm) with an angle of 120˚ between the two arms. After acclimatization, animals were first placed at the center of the maze, where which arms the mice explored for a period of 7 min was manually recorded. Spontaneous entry into and alternations between the three different arms were defined and recorded as continuous selection. The number of arm entries was also recorded. Before each trial, the arms were thoroughly cleaned with clean water to remove any odors.

**Open field test (OFT) protocol.** The OFT is a well-accepted assessment to evaluate anxiety, basic locomotor-activity and exploratory behavior in mice (11). At the end of the 28 day treatment, animals were placed at the center of a square arena (500x500 mm) at the beginning of the trial and were allowed to explore freely for 5 min. Locomotor activity was then recorded using a camera, following which the videos were analyzed using Noldus Ethovision XT 8.5 (Noldus Information Technology). The time spent by the mice at the center was recorded.

**Brain tissue collection and histopathology.** At the end of the behavioral experiments, the mice were sacrificed by decapitation to collect brain tissue. Half of the brain tissue was used for biochemical detection, whilst the other half was used for histological analysis. The intact brain tissue was quickly removed, where the bilateral hippocampus was separated on ice and stored at -80˚C until biochemical assays were performed.

The collected brain tissue was fixed in 4% paraformaldehyde at 4˚C overnight and preserved in 20% and 30% sucrose solution at 4˚C. The thickness of the brain slices was 35 μm. For the quantification of the staining, 5-6 sections with the same interval (70 μm) from each animal were analyzed. AB plaques were characterized by staining the sections with 0.1% thioflavin-S (Sigma-Adrich; Merck KGaA) in 50% ethanol for 10 min at room temperature, following which the sections were washed with ethanol three times. All stained sections were observed by laser scanning confocal microscopy (magnification, x200; A1+; Nikon Corporation). The number and intensity of the plaques were evaluated using the Image Pro Plus 6.0 Software (Media Cybernetics, Inc.). Hematoxylin and eosin (HE) staining performed at room temperature was used to evaluate neuronal cell morphology and images were taken under a light microscope (magnification, x100; CX43; Olympus Corporation).

**TUNEL assay.** Apoptosis was examined by performing TUNEL assays using the in situ Cell Death Detection kit (Roche Diagnostics GmbH), according to the manufacturer’s protocols. 35 μm cryosections of hippocampus were fixed in 4% paraformaldehyde at room temperature for 1 h, treated with 0.1% NaBH₄ and 0.1% Triton X-100 at room temperature for 1 h, and incubated at room temperature for 1 h with deoxy-nucleotidyl transferase and FITC-DUDP (Roche Diagnostics). The slides were then incubated in the dark with DAPI (Vector Laboratories, Inc.) for 15 min at room temperature. A total of 4-6 fields of vision were randomly selected under the microscope when each section was observed (magnification, x200) using a fluorescence microscope (Olympus Corporation) and the nuclei were visualized by aid of DAPI staining.

**Immunofluorescence.** Brain sections (35 μm) were blocked in 0.1M PBS containing 0.3% (v/v) Triton X-100 and 3% (v/v) normal goat serum (Gibco; Thermo Fisher Scientific, Inc.) at room temperature for 1 h, and incubated with primary antibodies against neuronal nucleoprotein (NeuN; rabbit; 1:100; cat. no. ab104225; Abcam) at room temperature for 2 h, followed by an overnight incubation at 4˚C. The next day, the sections were stained with Cy3-conjugated secondary antibodies (anti-rabbit Alexa488 conjugated secondary antibody; Sigma-Aldrich; Merck KGaA ; 1:200) for 1 h at room temperature and the sections were examined using laser
scanning confocal microscopy (A1+; Nikon Corporation) with magnification, x200. Samples were analyzed using the same exposure time of 10 ms in the region of interest module. Normalized fluorescence intensity was calculated for analysis using ImageJ v2.1.4.7 software (National Institutes of Health).

Western blotting. After the hippocampus was weighed and homogenized in RIPA buffer (Beyotime Institute of Biotechnology), protein concentration were determined using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology). Protein samples (40 µg) were separated using 15% SDS-PAGE and transferred onto PVDF membranes (EMD Millipore). After blocking with 3% skimmed milk at room temperature for 1 h, the membranes were incubated overnight at 4°C with primary antibodies (Cell Signaling Technology, Inc.) against cleaved caspase 3 (rabbit; 1:1,000; cat. no. 9661), caspase 3 (rabbit 1:1,000; cat. no. 9662), interleukin (IL)-1β (rabbit; 1:1,000; cat. no. 12703), tumor necrosis factor (TNF)-α (rabbit; 1:1,000; cat. no. 11948), inhibitor of NF-κBα (IκBα; mouse 1:1,000; cat. no. 9242), NF-κB p65 (rabbit; 1:1,000; cat. no. 8242), β-actin (1:10,000; cat. no, AS014; AbSci), NeuN (cat. no. MAB377; mouse; 1:300; Chemicon International), GFAP (mouse cat. no. Z033410,1:500; DAKO), and Iba1 (rabbit; cat. no. MABN92; 1:300; EMD Millipore). The following day, membranes were incubated with horse-radish peroxidase-conjugated anti-rabbit IgG secondary antibody (1:20,000; CWBIO) or HRP-conjugated anti-mouse IgG (1:10,000; Santa Cruz Biotechnology, Inc.) for 1 h at room temperature. Proteins were detected using chemiluminescence reagents (GE Healthcare Life Sciences) and the band intensity was analyzed using Image Pro Plus 6.0 Software (Media Cybernetics).

Figure 1. Therapeutic effects of SSD on memory impairment in 3xTg mice. (A-C) For the Morris water maze test, mice were trained to find the escape platform on the first day, following which the trial was performed three times a day for 5 days. (A) Escape latency and (B) quadrant time were recorded automatically. On the second to last day of training, the platform was removed and the (C) probe latency was recorded. (D and E) Elevated Y-Maze test. (D) 3xTg mice treated with SSD showed higher spontaneous alternation rates. (E) There was no significant difference among the groups in terms of number of arm entries. (F) 3xTg mice treated with SSD spent more time at the centre of the area in the open field test compared with that by untreated 3xTg mice. (G) Representative trail track in the open field test. One-way ANOVA was used for statistical analyses. Data are presented as the mean ± SEM. N=12 per group. *P<0.01 vs. 3xTg and **P<0.01 vs. WT. WT, wild-type; SSD, Saikosaponin D.
Statistical analysis. Data were analyzed using the GraphPad Prism 7 software (GraphPad Software, Inc.). All tests shall be repeated at least three times, and the data are presented as the mean±SEM. Multiple groups were compared by one-way ANOVA followed by the Student-Newman-Keuls post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

SSD treatment significantly improves memory deficits in 3xTg mice. To investigate whether SSD treatment could mitigate the memory impairments, a MWM, elevated Y-maze and OFT were performed. All tests were performed on 9-month-old 3xTg mice that had received SSD treatment for a period of 28 days. On the first day, mice were trained to find a platform. Subsequently, the test was performed three times a day for 5 days. The 3xTg + SSD mice exhibited shorter latencies for reaching the platform compared with those in the 3xTg mice (Fig. 1A). In the MWM test, 3xTg mice demonstrated significant memory deficits compared with those in the WT group, as indicated by the decreased time spent in the target quadrant (Fig. 1B) and increased probe latency (Fig. 1C). SSD treatment significantly increased the time spent by the 3xTg mice in the target quadrant and reduced probe latencies (Fig. 1B and C).

In the elevated Y-maze, SSD treatment increased the spontaneous alternation rate of 3xTg mice (Fig. 1D), whilst no significant differences were observed among the three groups in terms of the number of arm entries (Fig. 1E).

In the OFT, 3xTg mice that received SSD treatment exhibited less anxious behavior compared with that in the 3xTg mice, which spent less time at the center of the arena.
Therefore, these results indicated that SSD treatment significantly improved the memory deficits of 3xTg mice.

**SSD treatment alleviates pathomorphological deterioration and neuronal apoptosis in the hippocampus of 3xTg mice.** HE staining and immunofluorescence were performed to evaluate the changes in the pathological features of AD in the hippocampus of 3xTg mice after SSD treatment. In the WT group, Cornu Amonis 1 (CA1) neurons exhibited well-organized architecture, characterized by a normal shape and clear nuclei (Fig. 2A). However, CA1 neurons in 3xTg mice had a pyramidal appearance and shrinkage of nuclei. In addition, it was demonstrated that SSD treatment could abrogate these pathological features (Fig. 2A). Immunofluorescence (Fig. 2B) and western blotting (Fig. 2C) results revealed significantly increased NeuN-positive cells and NeuN expression in the 3xTg + SSD group compared with those in the 3xTg group, indicating increased numbers of neurons in the CA1 region after SSD treatment.

As neuronal apoptosis is a typical feature of AD that is associated with memory dysfunction (14), the effects of SSD on neuronal cell apoptosis were examined in the hippocampus using TUNEL staining. It was found that 3xTg mice exhibited severe apoptosis compared with the WT mice, whilst 3xTg + SSD mice exhibited markedly reduced TUNEL-positive cells in the CA1 neurons of the hippocampus compared with those in the 3xTg mice (Fig. 2D). Collectively, it was suggested that SSD may have a neuroprotective effect in the hippocampal CA1 area of 3xTg mice.

**SSD treatment reduces Aβ plaque deposition in the brain tissue of 3xTg mice.** Since Aβ accumulation in the cortex is one of the pathological characteristics of AD (3), thioflavin-S staining was used to evaluate the effect of SSD administration on Aβ accumulation. It was identified that 3xTg mice exhibited significantly increased levels of Aβ plaque deposition compared with those in the WT mice (Fig. 3). After SSD treatment, a significant reduction in the number (Fig. 3B) and intensity (Fig. 3C) of Aβ plaques was found in the 3xTg + SSD group compared with those in the 3xTg group, suggesting a potential inhibitory effect of SSD on Aβ deposition.

**SSD inhibits the activation of microglia and astrocytes in the hippocampus.** It has been previously reported that the activation of glial cells in the hippocampus is a characteristic feature of AD (3). Therefore, the present study investigated the activation of microglia and astrocytes by immunohistochemical staining. The number of ionized calcium binding adaptor molecule 1 (Iba1)-positive cells (microglia) and glial fibrillary
acidic protein (GFAP)-positive cells (astrocytes) was revealed to be increased in the hippocampus of 3xTg mice, whilst SSD treatment significantly reduced the activation of glia cells (Fig. 4A and C).

To assess these results, the expression levels of Iba1 and GFAP were measured by western blotting. The results were consistent with the immunohistochemical staining and demonstrated a significant decrease in Iba1 (Fig. 4B) and GFAP (Fig. 4D) expression in 3xTg + SSD mice compared with those in 3xTg mice. Therefore, the results suggested that SSD treatment suppressed glial cell activation in 3xTg mice.

SSD exerts anti-neuroinflammatory and anti-apoptotic effects in 3xTg mice. As the activation of glial cells can produce inflammatory cytokines and contribute to neuronal apoptosis (3), western blotting was performed to assess the expression of proteins associated with inflammatory cytokines. It was found that 3xTg + SSD mice exhibited significant reductions in the expression of cleaved caspase 3 compared with that in 3xTg mice, indicating the decline of apoptosis in the hippocampus following SSD treatment (Fig. 5A).

In addition, 3xTg mice had significantly higher hippocampal expression levels of IL-1β and TNF-α compared with those in the WT mice. SSD treatment reduced the expression levels of these inflammatory cytokines, suggesting that SSD can mediate anti-inflammatory effects.

The NF-κB signaling pathway controls the transcription of a number of genes associated with inflammation and defects in NF-κB can lead to an increase in the susceptibility to apoptosis (15). The present study therefore assessed if these anti-inflammatory and anti-apoptosis effects of SSD occurred via the inhibition of the NF-κB p65 signaling pathway. In the hippocampus of 3xTg mice, the expression levels of IκBα and NF-κB p65 were found to be increased, but this effect was significantly suppressed by SSD treatment (Fig. 5B). Collectively, these results suggested that SSD-mediated anti-neuroinflammatory and anti-apoptotic protection may be associated with suppression of the NF-κB signaling pathway.

Discussion

To the best of our knowledge, the present study was the first to report the effects of SSD on memory impairment and pathological characteristics of AD in 3xTg mice. The effects of SSD on memory impairment, Aβ plaque deposition and hippocampal neuroinflammation were investigated in a transgenic mouse model of AD. In addition, it was demonstrated that SSD has anti-amyloidogenic properties and anti-neuroinflammatory effects, in turn improving neuronal survival and memory deficits and preventing neuronal apoptosis in 3xTg mice via suppression of the NF-κB signaling pathway.

AD is a neurodegenerative disease that usually occurs in the elderly, where memory impairment is an early symptom of AD, followed by cognitive impairments and a decline in social competence (16). Patients with AD may also eventually lose language ability and are not able to live independently (17).

In recent years, 3xTg mice have been used to study AD, since they share similar clinicopathological characteristics with patients with AD, including memory impairments, early-onset brain amyloidosis, neuronal apoptosis and permanent loss of neurons (18,19). Therefore, the present study used the 3xTg mouse model to evaluate the ability of SSD in alleviating these clinicopathological characteristics.

Spatial learning and memory deficits are two typical features of patients with AD and mouse models of AD (20). In the present study, in the MWM test, 3xTg mice exhibited impaired learning and memory behavior. SSD treatment of these mice significantly reduced the escape latency and increased the time spent in the target quadrant, while decreasing the probe latency in the probe test. It was found that SSD treatment also increased the spontaneous alternation rate of 3xTg mice in the Y-maze. Therefore, it was speculated that SSD treatment was able to reduce the severity of the memory impairments in 3xTg mice.

Clinically, ~70% patients with AD experience symptoms of anxiety (21). Results from the present
study suggested that 3xTg mice treated with SSD were less anxious compared with 3xTg mice during the OFT, suggesting that SSD may also be able to ameliorate symptoms of anxiety.

Previous studies have reported that morphologic changes to neurons in the hippocampus contribute to the progression of AD, inducing impairments in learning and memory (19,20). A previous assessment of the clinical relevance of the model revealed that the 3xTg mice have characteristics of damaged neuronal structures, decreased fibre density and synaptic dysfunction in the hippocampus, similar to the AD pathology in humans (22). In the present study HE staining was performed, where it was identified that the CA1 neurons of 3xTg mice exhibited a pyramidal appearance and shrunken nuclei, but SSD treatment reversed these changes to features comparable to that of WT CA1 neurons. Additionally, increases in NeuN-positive cells and the lower TUNEL signal density suggested reduced neuronal loss and lower rates of apoptosis in the hippocampus of 3xTg mice after SSD treatment.

The formation of extracellular diffuse and fibrillar amyloid plaques, which consist of the Aβ peptide, is one of the hallmark pathologies of AD. The severity of AD has been previously found to be positively correlated with Aβ plaque accumulation in patients with AD (23,24). Targeting the aggregation of Aβ have been shown to be a promising therapeutic approach in treating AD (25). Although Lee et al (12) have also reported that SSC significantly suppresses the release of Aβ peptides in cell culture supernatants, whether SSD can suppress Aβ deposition in vivo is not fully understood. In the present study, 3xTg mouse brain sections stained with thioflavin-S exhibited an increase in Aβ plaque number and signal intensity compared with those from WT mice. In addition, treatment of 3xTg mice with SSD significantly reduced Aβ plaque deposition, suggesting that SSD can suppress Aβ plaque deposition in vivo in 3xTg mice. Glial cell activation is one of the pathological manifestations of AD (26). It has been suggested that the activation of glial cells may contribute to Aβ release (27), resulting in neuronal dysfunction and neuroinflammation, leading to the progression of AD (28). Immunohistochemistry staining results in the present study demonstrated that the increased Iba1 and GFAP expression in the hippocampus of 3xTg mice was reversed by SSD treatment, suggesting that microglia and astrocyte activation was reduced.

Neuroinflammation and apoptosis are two well-established processes that contribute to the production of Aβ and neuronal loss in AD (29,30). ILs, including IL-1β and TNF-α, strongly influence inflammatory responses (31). Li et al (32) previously revealed that SSA suppresses the concentrations of IL-1β and TNF-α in Aβ-treated C57BL/6 mice. In line with these findings, the present results suggested that the increases in the expression of IL-1β and TNF-α in the hippocampus of 3xTg mice were inhibited by SSD treatment. Apoptosis serves a central role in the pathogenesis of AD (33). It was demonstrated that caspase 3 cleavage, a key process in the activation of apoptosis, was reduced after SSD treatment in 3xTg mice.
Therefore, it was speculated SSD may be an effective treatment strategy against neuroinflammation and apoptosis.

The activation of the NF-κB signaling pathway may regulate the release of inflammatory cytokines and apoptosis, which serves a critical role in AD (34). Post-mortem studies have reported an increased expression and activation of NF-κB in the brains of patients with AD, particularly in regions commonly affected by AD including the hippocampus, entorhinal cortex, amygdala and different areas of neocortex (35). In the cytoplasm, the p65/p50 complex appears the most abundant, where the inhibitory effect of IκB on NF-κB is exerted primarily via its interaction with p65 (36,37). NF-κB normally regulates the expression of anti-apoptotic proteins such as the B-cell lymphoma-extra-large protein (38). However, overexpression of NF-κB may induce pro-apoptotic protein expression, which ultimately results in programmed cell death (38). In addition, it has previously been revealed that NF-κB can upregulate apoptosis and inflammation in AD (39). NF-κB activation following Aβ treatment has been identified in glia cultures, resulting in the increased expression levels of IL-1β and IL-6 (40). Therefore, it was speculated that the underlying mechanism through which SSD improves the symptoms of AD may involve downregulation of the NF-κB signaling pathway.

In the present study, concomitant with NF-κB activation, IκBα was also upregulated in the hippocampus of 3xTg mice, consistent with the D-galactose-induced rat AD model (41), which was suppressed by treatment with SSD. However, the underlying mechanism remains elusive. It was speculated that both NF-κB and IκBα may serve as SSD targets for inhibiting the symptoms in 3xTg mice. The present results indicated that SSD attenuated the increase expression levels of IκBα and NF-κB in 3xTg mice. These results were in line with previous studies, which revealed that guggulsterone exerted anti-inflammatory effects by blocking the IκBα/NF-κB signaling pathway (42). This indicates that SSD may confer anti-neuroinflammatory and anti-apoptotic effects via the suppression of the NF-κB p65 signaling pathway. Therefore, the present results may further the understanding of the functional target of SSD in its anti-neuroinflammatory properties.

In conclusion, SSD may improve memory impairments of 3xTg mice by reducing Aβ plaque deposition and glial cell activation in the hippocampus. The present study demonstrated that the neuroprotective effects of SSD involved the regulation of cell apoptosis and inflammation via inhibition of NF-κB activation. Therefore, the present study demonstrated the promising potential of SSD in the management of AD and identified the potential underlying mechanism of action of its beneficial effects.

Acknowledgements

Not applicable.

Funding

This study was funded by Medical and Health Research Projects of Wuhan Health Planning Commission (grant no. WZ15A05).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

All authors: LZ, JYH, DZ and YLZ contributed toward data analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Ethics approval and consent to participate

All experiments were performed according to the Guidelines for Animal Experimentation issued by the Ministry of Science and Technology of China. All animal experiments were approved by the Ethics Committee for Animal Experimentation of the Wuhan Hospital of Traditional Chinese Medicine (approval no. SYXK-2018-0213; Wuhan, China).

Patient consent for publication

No applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D and Jones E: Alzheimer's disease. Lancet 377:1019-1031, 2011.
2. Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frölich L, Riepe MW, Dodel R, Leyhe T, Bertram L, et al: The future of Alzheimer's disease: The next 10 years. Prog Neurobiol 95:718-728, 2011.
3. Selkoe DJ: The molecular pathology of Alzheimer's disease. Neuron 6:487-498, 1991.
4. Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobágyi T, Höglund K, Aarsland D, Lovestone S, Schöll M, Blennow K, et al: Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun 7, 5, 2019.
5. LeBlanc AC, Papadopoulos M, Bélair C, Chu W, Crosato M, Powell J and Goodyer CG: Processing of amyloid precursor protein in human primary neuron and astrocyte cultures. J Neurochem 68:1183-1190, 1997.
6. Gong J, Liu M, Xiao S, Jiang Y, Pan Y, Zhai Z, Luo Q, Yang L and Wang Y: Effects of light deficiency on the accumulation of saikosaponins and the ecophysiological characteristics of wild Bupleurum Chinense DC. In China. Industrial Crops Products 99:179-188, 2017.
7. Yen FL, Wang SW, Cheng HL, Chen KL and Chen YL: Determination of saikosaponins in bupleuri radix by micellar electrokinetic chromatography with experimental design. Anal Lett 51:1-14, 2018.
8. Dang SS, Wang BF, Cheng YA, Song P, Liu ZG and Li ZF: Inhibitory effects of saikosaponin-d on CCl4-induced hepatic fibrogenesis in rats. World J Gastroenterol 13:557-563, 2007.
9. Li XQ, Song YN, Wang SJ, Rahman K, Zhu JY and Hong Z: Saikosaponins: A review of pharmacological effects. J Asian Nat Prod Res 20:399-411, 2018.
10. Li Y, Cai T, Zhang W, Zhu W and Ly S: Effects of saikosaponin D on apoptosis in human U87 glioblastoma cells. Mol Med Rep 16:1459-1464, 2017.
11. Sun X, Li X, Pan R, Xu Y, Wang Q and Song M: Total saikosaponins of bupleurum yinchowense reduces depressive, anxiety-like behavior and increases synaptic proteins expression in chronic corticosterone-treated mice. BMC Complement Altern Med 18: 117, 2018.

12. Lee TH, Park S, You MH, Lim JH, Min SH and Kim BM: A potential therapeutic effect of saikosaponin C as a novel dual-target anti-Alzheimer agent. J Neurochem 136: 1232-1245, 2016.

13. Ali J, Khan AU, Shah FA, Ali H, Islam SU, Kim YS and Khan S: Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. Life Sci 239: 116888, 2019.

14. Cotman CW and Anderson AJ: A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol 10: 19-45, 1995.

15. Li N and Karim M: Signaling pathways leading to nuclear factor-kappa B activation. Methods Enzymol 319: 273-279, 2000.

16. Zhang MY, Katzman R, Salmon D, Jin H, Cai GJ, Wang ZY, Qu GY, Grant I, Yu E, Levy P, et al: The prevalence of dementia and Alzheimer's disease in Shanghai, China: Impact of age, gender, and education. Ann Neurol 27: 428-437, 1990.

17. Mizuno K, Wakai M, Takeda A and Sobue G: Medial temporal atrophy and memory impairment in early stage of Alzheimer's disease: An MRI volumetric and memory assessment study. J Neurol Sci 173: 18-24, 2000.

18. Knight EM, Martins IV, Gümrükgöz S, Allan SM and Lawrence CB: High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. Neurobiol Aging 35: 1821-1832, 2014.

19. Giménez-Llort L, Arranz L, Maté I and De la Fuente M: Gender-specific neuroimmunoendocrine aging in a triple-transgenic 3xTg-AD mouse model for Alzheimer's disease and its relation with longevity. Neuroimmunomodulation 15: 331-343, 2008.

20. Wilson KS, Barnes LL, Mendes de Leon CF, Aggarwal NT, Schneider JS, Horne P, Heslin D, French J, Chishti MA, Janus C, Pearson J, McLaurin J, et al: Mucoprotective effects of Saikosaponins in Alzheimer's disease. Altern Med 35: 1821-1832, 2014.

21. Kaur U, Banerjee P, Bir A, Sinha M, Biswas A and Chakraborti S: Reactive oxygen species, redox signaling and neuroinflammation in Alzheimer's disease: The NF-kappaB activation. Mol Neurobiol 10: 139-149, 2012.

22. Ali J, Khan AU, Shah FA, Ali H, Islam SU, Kim YS and Khan S: Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. Life Sci 239: 116888, 2019.

23. Cotman CW and Anderson AJ: A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol Neurobiol 10: 19-45, 1995.

24. Li N and Karim M: Signaling pathways leading to nuclear factor-kappa B activation. Methods Enzymol 319: 273-279, 2000.

25. Knight EM, Martins IV, Gümrükgöz S, Allan SM and Lawrence CB: High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. Neurobiol Aging 35: 1821-1832, 2014.

26. Zhang MY, Katzman R, Salmon D, Jin H, Cai GJ, Wang ZY, Qu GY, Grant I, Yu E, Levy P, et al: The prevalence of dementia and Alzheimer's disease in Shanghai, China: Impact of age, gender, and education. Ann Neurol 27: 428-437, 1990.

27. Mizuno K, Wakai M, Takeda A and Sobue G: Medial temporal atrophy and memory impairment in early stage of Alzheimer's disease: An MRI volumetric and memory assessment study. J Neurol Sci 173: 18-24, 2000.

28. Meda L, Baron P and Scarlato G: Glial activation in Alzheimer's disease: The role of Abeta and its associated proteins. Neurobiol Aging 22: 885-893, 2001.

29. Calsolaro V and Edison P: Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement 12: 719-732, 2016.

30. Wright AL, Zinn R, Hohensinn B, Konen LM, Beynon SB, Tan RP, Clark IA, Abdipranoto A and Vissel B: Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer’s disease. PLoS One 8: e59586, 2013.

31. Song Y, Qu R, Zhu S, Zhang R and Ma S: Rhyneohphylaceous attenuates LPS-induced pro-inflammatory responses through down-regulation of MAPK/NF-κB signaling pathways in primary microglia. Phytother Res 26: 1528-3135, 2012.

32. Li J, Biswas S, Niu Y, Li WQ, Sun N, Miao ZH and Yao Y: P23 Saikosaponin a ameliorate learning and memory impairment via anti-inflammatory effects in an AD mouse model. Biochem Pharmacol 139: 132, 2017.

33. Gemma C, Bachstetter AD, Cole MJ, Fister M, Hudson C and Bickford PC: Blockade of caspase-1 increases neurogenesis in the aged hippocampus. Eur J Neurosci 26: 2795-2803, 2007.

34. Chen CH, Zhou W, Liu S, Deng Y, Cai F, Tone M, Tone Y, Tong Y and Song W: Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. Int J Neuropsychopharmacol 15: 77-90, 2012.

35. Uau K, Banerjee P, Bir A, Sinha M, Biswas A and Chakraborti S: Reactive oxygen species, redox signaling and neuroinflammation in Alzheimer's disease: The NF-kB connection. Curr Top Med Chem 15: 446-457, 2015.

36. Zhong H, Voll RE and Ghosh S: Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1: 661-671, 1998.

37. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS Jr and Mayo MW: Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 20: 1626-1638, 2000.

38. Mursheed F, Farhana L, Dawson MI and Fontana JA: NF-κB p65 recruited SHP regulates PDCDS5-mediated apoptosis in cancer cells. Apoptosis 19: 506-517, 2014.

39. Liao Y, Qi XL, Cao Y, Yu WF, Ravid R, Winblad B, Pei JJ and Guan ZZ: Elevations in the levels of NF-κB and inflammatory chemotactic factors in the brains with Alzheimer's disease-one mechanism may involve α3 nicotinic acetylcholine receptor. Curr Alzheimer Res 13: 1290-1301, 2016.

40. Aisen PS and Davis KL: Inflammatory mechanisms in Alzheimer's disease: Implications for therapy. Am J Psychiatry 151: 1105-1113, 1994.

41. Gao J, Zhou R, You X, Luo F, He H, Chang X, Zhu L, Ding X and Yan T: Salidroside suppresses inflammation in a D-galactose-induced rat model of Alzheimer's disease via SIRT1/NF-κB pathway. Metab Brain Dis 31: 771-778, 2016.

42. Huang C, Wang J, Lu X, Hu W, Fu J, Jiang B, Ling Y, Yang R and Zhang W: Z-guggulsterone negatively controls microglia-mediated neuroinflammation via blocking kB-α-NF-κB signals. Neurosci Lett 619: 34-42, 2016.